| abstract |
The present invention relates to .alpha.7 nicotinic receptor agonists of formula (I) as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal an .alpha.7 nicotinic receptor agonist of formula (I). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant .alpha.7 nicotinic receptor agonist of formula (I). |